Ashley Stevens, Director of the Office of Technology Transfer, Boston University
Labeeb Abboud, Senior Vice President and General Counsel, International AIDS Vaccine Initiative
What do we know about the adoption of policies within universities to specifically address humanitarian applications of university research results? Does the data indicate that universities could be doing more?
What is/should be the process within institutions to assess the potential humanitarian application of research results/invention disclosures? Who is involved? Is there an established process or is it case by case? Does it tend to be instigated by investigators or from outside the institution-student groups? Non-governmental organizations? Research sponsors?
Are there different licensing terms for discoveries with potential to relieve poverty, hunger, disease, and environmental degradation in poor countries? How do licensing terms differ for discoveries with first world applications that do not promise to become commercial markets (e.g., orphan disease treatments)? From discoveries with applications that promise significant commercial markets?
In what circumstances have pools of IP owned by universities overcome barriers to humanitarian applications of research advances? Has the experience been successful? What would you do differently or advise other institutions to do differently?
There seems to have been progress in addressing the IP needs for certain areas of health and agricultural development. Are there emerging technology sectors needed for global development that represent the next big challenges? How can universities position themselves now to address emerging challenges?
Our discussion has largely focused on patented technologies. What about access to information and materials? To what extent should universities focus their attention in these areas and with what relative priority?
3:00 PM to 3:30 PM
Session 6: Open Discussion